Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

NGF activation of TrkA decreases N-myc expression via MAPK path leading to a decrease in neuroblastoma cell number.

Chan-Wook Woo1, Enrico Lucarelli, Carol J Thiele

  • 1Cell & Molecular Biology Section, Pediatric Oncology Branch, NCI, NIH, Bethesda, MD 20892, USA.

Oncogene
|December 24, 2003
PubMed
Summary

Nerve growth factor (NGF) reduces neuroblastoma growth by decreasing N-myc levels via the TrkA receptor and MAPK pathway, promoting cell differentiation and slowing proliferation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Comprehensive Summary of the Third International StemNet Meeting 2026.

Frontiers in bioscience (Landmark edition)·2026
Same author

Drug-loaded biomorphic scaffolds for tissue regeneration and targeted antitumor therapy in bone metastasis models.

Biomaterials advances·2026
Same author

FOS3D: A Fluorescence-Enabled Toolkit for Characterizing a Three-dimensional Osteosarcoma Model.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

SGSS05-NS3, a covalent SETD8 inhibitor that activates p53 pathway in neuroblastoma.

Journal of experimental & clinical cancer research : CR·2025
Same author

Establishment and Characterization of OS-MET-R-092: A Novel Patient-Derived Cell Culture from an Osteosarcoma Bone Metastasis.

International journal of molecular sciences·2025
Same author

GPC2-CAR T cells have potent preclinical activity against orthotopic medulloblastoma xenografts.

Molecular therapy. Oncology·2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Neuroblastoma (NB) prognosis is linked to TrkA receptor expression (good) and N-myc amplification (poor).
  • Reducing N-myc levels is crucial for controlling NB cell growth and inducing differentiation.

Purpose of the Study:

  • To investigate the mechanisms by which nerve growth factor (NGF) decreases N-myc levels in TrkA-transfected NB cells.
  • To determine the effect of NGF-induced N-myc reduction on NB cell proliferation.

Main Methods:

  • Treatment of TrkA-transfected NB cells with NGF and monitoring N-myc mRNA levels.
  • Utilizing cycloheximide to assess mRNA stability and Trk tyrosine kinase (TK) antagonist K252a to block signaling.
  • Employing pharmacologic inhibitors and MAPK pathway components (MEK) to identify signaling pathways involved.

Related Experiment Videos

Main Results:

  • NGF rapidly decreased N-myc mRNA transcriptionally, independent of mRNA stability.
  • The NGF effect was mediated through TrkA TK signaling, implicating the MAPK pathway.
  • NGF reduced NB cell proliferation by decreasing cyclin E-dependent kinase activity and increasing p27(kip1).

Conclusions:

  • NGF downregulates N-myc expression transcriptionally via the MAPK pathway in TrkA-expressing NB cells.
  • NGF influences NB cell cycle progression by modulating N-myc, E2Fs, cyclin E kinase activity, and p27(kip1) binding.